Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines

Human and Experimental Toxicology

Volumn 35, Issue 5, 2016, Pages 526-543

  Yar Saglam, A S ^a   Alp, E ^b   Elmazoglu, Z ^a   Menevse, S ^a  

^a GAZI UNIVERSITY   (Turkey)

^b GIRESUN UNIVERSITY   (Turkey)

Author keywords

apoptosis; colorectal cancer; Cucurbitacin B; gefitinib; HCT 116 cell line; HT 29 cell line

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; CASPASE 3; CUCURBITACIN B; CYCLIN D1; GEFITINIB; LACTATE DEHYDROGENASE; PROTEIN BAD; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; STAT PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE; QUINAZOLINE DERIVATIVE; TRITERPENE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ASSAY; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY ASSAY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY ASSAY; DNA FRAGMENTATION; DNA SYNTHESIS; ENZYME RELEASE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; HCT116 CELLS; HT29 CELLS; HUMANS; JANUS KINASES; MICROSCOPY, FLUORESCENCE; QUINAZOLINES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRITERPENES;

EID: 84964735360     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327115595686     Document Type: Article

References (68)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
2. Mendelsohn J, Baselga J,. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19 (56): 6550-6565.
3. Jorissen RN, Walker F, Pouliot N, et al.Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284 (1): 31-53.
4. Normanno N, De Luca A, Bianco C, et al.Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2-16.
5. Krasinskas AM,. EGFR signaling in colorectal carcinoma. Patholog Res Int 2011; 2011: 932932.
6. Ciardiello F, Tortora G,. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7 (10): 2958-2970.
7. Arteaga CL, Johnson DH,. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 2001; 13: 491-498.
8. Wakeling AE, Guy SP, Woodburn JR, et al.ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62 (20): 5749-5754.
9. Douglass EC,. Development of ZD1839 in colorectal cancer. Semin Oncol 2003; 30: 17-22.
10. Koizumi F, Kanzawa F, Ueda Y, et al.Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa†) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108 (3): 464-472.
11. Xu JM, Azzariti A, Colucci G, et al.The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 2003; 52 (6): 442-448.
12. Ciardiello F, Caputo R, Bianco R, et al.Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6 (5): 2053-2063.
13. Sirotnak FM,. Studies with ZD1839 in preclinical models. Semin Oncol 2003; 30 (1): 12-20.
14. Xiong H, Zhang ZG, Tian XQ, et al.Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 2008; 10 (3): 287-297.
15. Leonard WJ, O'Shea JJ,. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293-322.
16. Kisseleva T, Bhattacharya S, Braunstein J, et al.Signalling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1-24.
17. Aggarwal BB, Sethi G, Ahn KS, et al.Targeting signal transducer and activator of transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 2006; 1091: 151-169.
18. Clericuzio M, Mella M, Vita-Finzi P, et al.Cucurbitane triterpenoids from Leucopaxillus gentianeus. J Nat Prod 2004; 67: 1823-1828.
19. Chen JC, Chiu MH, Nie RL, et al.Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 2005; 22 (3): 386-399.
20. Escandell JM, Kaler P, Recio MC, et al.Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: The role of p53 and p21. Biochem Pharmacol 2008; 76 (2): 198-207.
21. Jayaprakasam B, Seeram NP, Nair MG,. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003; 189 (1): 11-16.
22. Zhang M, Zhang H, Sun C, et al.Targeted constitutive activation of signal transducer and activator of transcription 3 in human hepatocellular carcinoma cells by cucurbitacin B. Cancer Chemother Pharmacol 2009; 63 (4): 635-642.
23. Wakimoto N, Yin D, O'Kelly J, et al.Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 2008; 99 (9): 1793-1797.
24. Liu T, Zhang M, Zhang H, et al.Inhibitory effects of cucurbitacin B on laryngeal squamous cell carcinoma. Eur Arch Oto-Rhino-Laryngol 2008; 265 (10): 1225-1232.
25. Zhang M, Sun C, Shan X, et al.Inhibition of pancreatic cancer cell growth by cucurbitacin B through modulation of signal transducer and activator of transcription 3 signaling. Pancreas 2010; 39 (6): 923-929.
26. Lee DH, Thoennissen NH, Goff C, et al.Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 2011; 306 (2): 161-170.
27. Haritunians T, Gueller S, Zhang L, et al.Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells. Leuk Res 2008; 32 (9): 1366-1373.
28. Yasuda S, Yogosawa S, Izutani Y, et al.Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 2010; 54 (4): 559-565.
29. Pfaffl MW, Horgan GW, Dempfle L,. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30 (9): e36.
30. Elmore S,. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35 (4): 495-516.
31. Asakura T, Ohkawa K,. Chemotherapeutic agents that induce mitochondrial apoptosis. Curr Cancer Drug Targets 2004; 4 (7): 577-590.
32. Fulda S,. Modulation of apoptosis by natural products for cancer therapy. Planta Med 2010; 76 (11): 1075-1079.
33. Lien K, Berry S, Ko YJ, et al.The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective? Expert Rev Pharmacoecon Outcomes Res 2014; 17: 1-20.
34. Luca T, Barresi V, Privitera G, et al.In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif 2014; 47 (5): 435-447.
35. Frank DA,. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007; 251 (2): 199-210.
36. Qi QR, Yang ZM,. Regulation and function of signal transducer and activator of transcription 3. World J Biol Chem 2014; 5 (2): 231-239.
37. Safarzadeh E, Sandoghchian Shotorbani S, Baradaran B,. Herbal medicine as inducers of apoptosis in cancer treatment. Adv Pharm Bull 2014; 4 (1): 421-427.
38. Ouyang L, Luo Y, Tian M, et al.Plant natural products: from traditional compounds to new emerging drugs in cancer therapy. Cell Prolif 2014; 47 (6): 506-515.
39. Hasima N, Ozpolat B,. Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 2014; 5: 1509.
40. Liu T, Zhang M, Zhang H, et al.Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol 2008; 587 (1-3): 78-84.
41. Liu T, Zhang M, Deng Y, et al.Effects of cucurbitacin B on cell proliferation and apoptosis in Hep-2 cells. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008; 22 (9): 403-407.
42. Iwanski GB, Lee DH, En-Gal S, et al.Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer. Br J Pharmacol 2010; 160 (4): 998-1007.
43. Liu T, Peng H, Zhang M, et al.Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol 2010; 641 (1): 15-22.
44. Bhattacharyya NP, Skandalis A, Ganesh A, et al.Mutator phenotypes in human colorectal carcinoma cell lines. Proc Natl Acad Sci U S A 1994; 91 (14): 6319-6323.
45. Yao K, Gietema JA, Shida S, et al.In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo. Br J Cancer 2005; 93 (12): 1356-1363.
46. Lurje G, Lenz HJ,. EGFR signaling and drug discovery. Oncology 2009; 77 (6): 400-410.
47. Chao TT, Wang CY, Lai CC, et al.TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. J Pharmacol Exp Ther 2014; 351 (2): 352-358.
48. Song JY, Kim CS, Lee JH, et al.Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. Invest New Drugs 2013; 31 (6): 1458-1465.
49. Patel BB, Gupta D, Elliott AA, et al.Curcumin targets FOLFOX-surviving colon cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res 2010; 30 (2): 319-325.
50. Solmi R, Lauriola M, Francesconi M, et al.Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer 2008; 8: 227.
51. Duangmano S, Dakeng S, Jiratchariyakul W, et al.Antiproliferative effects of cucurbitacin B in breast cancer cells: down-regulation of the c-Myc/hTERT/telomerase pathway and obstruction of the cell cycle. Int J Mol Sci 2010; 11 (12): 5323-5338.
52. Gao Y, Islam MS, Tian J, et al.Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Lett 2014; 349 (1): 15-25.
53. Zhang M, Bian ZG, Zhang Y, et al.Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep 2014; 10 (6): 2905-2911.
54. Thoennissen NH, Iwanski GB, Doan NB, et al.Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69 (14): 5876-5884.
55. Chan KT, Meng FY, Li Q, et al.Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 2010; 294 (1): 118-124.
56. Schultz DR, Harrington WJ,. Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum 2003; 32 (6): 345-369.
57. Guo J, Zhao W, Hao W, et al.Cucurbitacin B induces DNA damage, G2/M phase arrest, and apoptosis mediated by reactive oxygen species (ROS) in leukemia K562 cells. Anticancer Agents Med Chem 2014; 14 (8): 1146-1153.
58. Zhang Y, Ouyang D, Xu L, et al.Cucurbitacin B induces rapid depletion of the G-actin pool through reactive oxygen species-dependent actin aggregation in melanoma cells. Acta Biochim Biophys Sin (Shanghai) 2011; 43 (7): 556-567.
59. Zheng Q, Liu Y, Liu W, et al.Cucurbitacin B inhibits growth and induces apoptosis through the JAK2/STAT3 and MAPK pathways in SHâ€'SY5Y human neuroblastoma cells. Mol Med Rep 2014; 10 (1): 89-94.
60. Dakeng S, Duangmano S, Jiratchariyakul W, et al.Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin to the nucleus. J Cell Biochem 2012; 113 (1): 49-60.
61. Zhu JS, Ouyang DY, Shi ZJ, et al.Cucurbitacin B induces cell cycle arrest, apoptosis and autophagy associated with G actin reduction and persistent activation of cofilin in Jurkat cells. Pharmacology 2012; 89 (5-6): 348-356.
62. Feng Y, Dai X, Li X, et al.EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis. Cell Prolif 2012; 45 (5): 413-419.
63. Müller KM, Tveteraas IH, Aasrum M, et al.Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC Cancer 2011; 11: 421.
64. Bianco C, Tortora G, Bianco R, et al.Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8 (10): 3250-3258.
65. Chan KT, Li K, Liu SL, et al.Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 2010; 289 (1): 46-52.
66. Ge YQ, Xu XF, Yang B, et al.Saponins from Rubus parvifolius L. induce apoptosis in human chronic myeloid leukemia cells through AMPK activation and STAT3 inhibition. Asian Pac J Cancer Prev 2014; 15 (13): 5455-5461.
67. Shields BJ, Wiede F, Gurzov EN, et al.TCPTP regulates SFK and STAT3 signaling and is lost in triple-negative breast cancers. Mol Cell Biol 2013; 33 (3): 557-570.
68. Sen M, Joyce S, Panahandeh M, et al.Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012; 18 (18): 4986-4996.